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Abstract
Background: Sickle cell disease is the commonest genetic disorder in Jamaica and most likely
exerts numerous effects on quality of life (QOL) of those afflicted with it. The WHOQOL-Bref,
which is a commonly utilized generic measure of quality of life, has never previously been utilized
in this population. We have sought to study its utility in this disease population.
Methods: 491 patients with sickle cell disease were administered the questionnaire including
demographics, WHOQOL-Bref, Short Form-36 (SF-36), Flanagan's quality of life scale (QOLS) and
measures of disease severity at their routine health maintenance visits to the sickle cell unit.
Internal consistency reliabilities, construct validity and "known groups" validity of the WHOQOL-
Bref, and its domains, were examined; and then compared to those of the other instruments.
Results: All three instruments had good internal consistency, ranging from 0.70 to 0.93 for the
WHOQOL-Bref (except the 'social relationships' domain), 0.86–0.93 for the SF-36 and 0.88 for the
QOLS. None of the instruments showed any marked floor or ceiling effects except the SF-36
'physical health' and 'role limitations' domains. The WHOQOL-Bref scale also had moderate
concurrent validity and showed strong "known groups" validity.
Conclusion: This study has shown good psychometric properties of the WHOQOL-Bref
instrument in determining QOL of those with sickle cell disease. Its utility in this regard is
comparable to that of the SF-36 and QOLS.
Background
Sickle cell disease (SCD) is the commonest genetic disor-
der in Jamaica with the sickle hemoglobin (HbS) gene
being present in about 10% of the population. It includes
a variety of pathological conditions [1] and affects the
individual throughout their life cycle. In Jamaica, SCD has
become a significant indirect cause of maternal mortality
[2] and contributes as a causative factor to 0.7% of cases
of chronic renal failure [3]. It has also been presented as
one of the 10 most common causes of sudden death in
Jamaica accounting for 2.5% of cases [4]. Among those
with homozygous sickle cell disease (SS) in Jamaica, there
is a 50% survival to 30 to 40 years. Median survival is cal-
culated at 53 years for men and 58.5 for women [5].
SCD carries a huge psychosocial burden impacting on
physical, psychological, social and occupational well-
being as well as levels of independence [6-14]. Psycholog-
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from the impact of pain and symptoms on their daily lives
and society's attitudes towards them [15-17]. Generally,
there is increased psychological morbidity such as depres-
sion and poor coping [9,10,18-22], and poorer quality of
life (QOL) [9,14,23].
The Short-Form 36 (SF-36) has been validated for measur-
ing QOL in this population [24], but the World Health
Organization Quality of Life- BREF (WHOQOL-BREF)
has never been studied in these patients. Whereas the SF-
36 provides some measure of functional status along with
health related QOL, the WHOQOL-BREF measures rela-
tively broader and totally subjective domains [25-27]. Its
particular strength lies in the fact of its cross-cultural
development employing elements of emic and etic per-
spectives [28], and as the Jamaican population represents
a forging of different ethnicities as well as distinct cultures
[29], the WHOQOL-Bref may prove to be a stronger meas-
ure of QOL. The Flanagan's quality of life scale (QOLS) is
a generic scale but has had particular adaptation for use
among persons with chronic diseases [30]. A comparison
of these generic instruments will allow further study of
their possible weaknesses and strengths. Therefore, the
specific aims of this study are to: i) assess the properties of
WHOQOL-BREF in SCD; and ii) compare the properties
of the WHOQOL-BREF, SF-36 and QOLS in SCD.
In the current study we expected that the WHOQOL -
physical subscale should be strongly correlated (r ≥ 0.50)
with SF-physical health, role limitations and total scores,
but less correlated (r ≤ 0.30) with SF-mental health scores
as this subscale assesses the physical state of patient's
quality of life. We expect a smaller correlation (r ≥ 0.30)
with clinical indicators such as haemoglobin and serum
lactate dehydrogenase (LDH). WHOQOL-psychological
health domain may be strongly correlated (r ≥ 0.50) with
the SF-mental health, SF-36 total score and the QOLS, but
only moderately (r ≤ 0.30) with SF-physical health and
role limitations subscales. The WHOQOL-social relations
and environment subscales are expected to be strongly
correlated (r ≥ 0.50) with the SF-mental health subscale,
the SF-36 total score and the QOLS scale, but less (r ≤
0.30) with the SF-physical and role limitations subscales,
and (r ≤ 0.30) with haemoglobin and LDH. Finally, we
expect the total WHOQOL-Bref score to be strongly corre-
lated (r ≥ 0.50) with the total SF-36 and QOLS scores.
Methods
Study population
This was designed as a cross-sectional study. The Sickle
Cell Unit (SCU) in Kingston operates Jamaica's only com-
prehensive sickle cell centre. All adults over the age of 18
years, registered at the SCU for at least 1 year, and present-
ing for health maintenance visit from January to June
2005 were invited to take part and none declined.
Study Instruments
The SF-36, QOLS and WHOQOL-BREF (U.K.version)
were interviewer-administered (as only about 80% of
Jamaicans are considered to be functionally literate [31])
to all participants after they had signed an informed con-
sent form. Data were also collected on age, sex, genotype,
marital status, level of education achieved, employment
status and occupation.
Study Instruments
In past research, the WHOQOL-BREF has shown good to
excellent reliability and validity, and has four domains:
physical, psychological, social and environment [32].
Thomas et al [14], in their qualitative work with patients
who have SCD, have identified themes that are quite sim-
ilar to the core domains of the WHOQOL.
The psychometric properties of the SF-36 have been stud-
ied in the Jamaican population with SCD and it shows a
slightly different component structure [33] yielding three
distinct subscales: physical health, mental health and role
limitations.
QOLS is a reliable and valid 16 item generic instrument
[34]., and was selected for use as it has been extensively
used in chronic conditions and provides a subjective, glo-
bal evaluation of QOL.
Data on participants' clinical variables, such as frequency
of painful crises in past year, haemoglobin levels, serum
creatinine and LDH levels, were obtained from their med-
ical records. The study was granted ethical approval by the
University of the West Indies/University Hospital of the
West Indies, Faculty of Medical Sciences Ethics Commit-
tee.
Statistical approach
All data were initially captured into Epidata® for Windows
and then analyzed with Stata™ statistical software for Win-
dows version 8.2 [35].
Domain scores for the WHOQOL were transformed to a
4–20 score according to accepted guidelines [36]. Cron-
bach's alpha values of .70 and over were deemed accepta-
ble [37]. The floor and ceiling effects were measured for
the scales and their domains with floor effect being the
percentage of subjects with the lowest possible domain
scores and the ceiling effect being the percentage of sub-
jects with the highest possible domain scores.
The psychometric properties were further tested by meas-
uring the "known-groups" construct validity. The pres-Page 2 of 6
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complication of the disease [38,39], and those with
higher pain rates tend to die earlier than those with lower
pain rates [40]. Painful crises were defined as presence of
bony pains requiring opioid analgesics for relief, and cat-
egorized (less than or equal to 3 episodes per year or
greater than 3 episodes for the year). T-test was used to test
whether the scores in the three instruments could discrim-
inate among different categories.
Pearson's correlations were used to determine the level of
agreement between the three instruments, as well as with
markers of disease severity. As a general guideline, corre-
lations from 0.00 to 0.25 indicate little or no relationship,
from 0.25 to 0.50 a fair degree of relationship, from 0.50
to 0.75 a moderate to good relationship, and above 0.75
a good to excellent relationship [41].
Results
Demographics and clinical characteristics
A total of 491 patients participated (Table 1), consisting of
43% males and 57% females. The mean age was 31.3
years ± 9.6 years with a range from 18–70 years. The com-
monest genotypes were 68% SS (Homozygous S Disease)
disease and 21.5% SC (Heterozygous S-C Disease). Most
were 'single' (88%) with only 10% being 'married'. Only
51.5% were employed currently. 54% had a secondary
education, 24% had vocational training and 6% had a ter-
tiary education.
The mean haemoglobin was 9.0 ± 2.2 gm/dl; and fetal
haemoglobin was 4.6 ± 4.3%. The mean serum creatinine
and LDH were 60.4 ± 25.4 μmol/L and 391.7 ± 193.2 IU/
L respectively. 83.9% had 0–3 painful crises for the past
year and 16.1% had greater than 3.
Psychometric properties of the WHOQOL-Bref, QOLS 
and SF-36
The baseline means, standard deviations, minimum/max-
imum and internal consistency reliability coefficients for
all three instruments and their domains are summarized
in Table 2. All scales had moderate Cronbach's alpha
scores, ranging from 0.70 to 0.93, except the WHOQOL-
social relationship domain (0.66). The mean scores for
the WHOQOL-physical health and WHOQOL-environ-
ment were lower than the other domain scores. The SF-36
and QOLS had generally higher reliability coefficients
than the WHOQOL-Bref. Most domains had no marked
floor or ceiling effects (<1%), exceptions being WHO-
QOL-social relations (ceiling effect = 3.9%), SF-mental
health and SF-role limitations domains (ceiling effects
~19%).
Table 3 shows the known-groups validity where the mean
scores decreased, meaning lower quality of life on each
scale/domain, as frequency of painful crises increased (All
p < 0.01 for ANOVA).
Correlation analyses
Table 4 demonstrates the correlations of the WHOQOL-
Bref with SF-36, QOLS and clinical variables. The total SF-
36 and WHOQOL-Bref scores had an acceptable positive
correlation (0.64). The WHOQOL-Bref domains showed
moderate correlations with SF-36-mental health, ranging
from 0.51 for WHOQOL-social relationships to 0.59 for
WHOQOL-psychological, and with the total SF-36 score
(0.47–0.53). They had much stronger correlations with
the QOLS score, ranging from 0.43 for WHOQOL-physi-
cal to 0.71 for WHOQOL-environmental. The WHOQOL
total score correlation with the QOLS score was high at
0.75.
As expected, the clinical variables showed significant cor-
relations with WHOQOL-physical health: -0.34 with LDH
and 0.34 with haemoglobin. These variables also had
smaller, significant correlations with the total WHOQOL
score.
Discussion
The main purpose of this paper was to assess the utility of
this instrument in patients with SCD living in Jamaica. In
all of its performance measures, the WHOQOL-Bref has
Table 1: Demographic and clinical characteristics of the study 
population (n = 491)
Variable
Sex, M: F (%) 210 (42.7): 281 (57.3)








Vocational training 119 (24.2)
Tertiary 30 (6.1)





Haemoglobin g/dl, mean (SD) 9.0 (2.2)
Fetal Haemoglobin %, mean (SD) 4.6 (4.3)
Lactate Dehydrogenase IU/L, mean (SD) 391.73 (193.2)
Serum Creatinine μmol/L, mean (SD) 60.4 (25.4)
Painful Crises, n (%)
0–3 per year 412 (83.9)
More than 3 per year 79 (16.1)Page 3 of 6
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Table 2: Descriptive Statistics of all three measures and their domains*
Cronbachs Alpha Minimum Maximum Mean Std. Deviation Floor effect (%) Ceiling effect (%)
WHOQOL-Physical 0.87 7.43 20.00 13.96 2.71 0.2 0.8
WHOQOL-Psychological 0.82 6.67 19.33 14.18 2.12 0.2 0.4
WHOQOL- Social 
Relations
0.66 5.33 20.00 14.91 2.77 0.2 3.9
WHOQOL-Environment 0.81 7.50 19.00 13.38 2.24 1.0 0.2
Total WHOQOL Score 0.81 34.17 76.34 56.43 7.87 0.2 0.2
SF 36-Physical Health 0.86 10 30 26.46 3.49 0.4 19.1
SF36-Mental Health 0.93 15 45 32.45 6.21 0.2 0.4
SF36-Role Limitations 0.90 12.2 42 34.54 7.13 0.2 19.2
Total SF36 Score 0.70 48.2 117 93.46 13.81 0.2 0.4
QOLS Score 0.88 38 114 78.0 10.8 0.2 0.2
* Higher scores reflect better quality of life on each domain of all measures






WHOQOL-Physical 14.3 (14.0, 14.5) 12.3 (11.8,12.8) <0.001
WHOQOL-Psychological 14.3 (14.1, 14.5) 13.6 (13.1,14.1) 0.009
WHOQOL- Social Relations 15.1 (14.8, 15.3) 14.1 (13.4, 14.7) 0.004
WHOQOL-Environmental 13.5 (13.3, 13.7) 12.5 (11.9, 13.1) <0.001
Total WHOQOL Score 57.2 (56.4, 57.9) 52.6 (50.9, 54.3) <0.001
SF 36-Physical Health 26.7 (26.4, 27.0) 25.2 (24.4, 26.0) <0.001
SF36-Mental Health 33.1 (32.6, 33.7) 28.9 (27.5, 30.3) <0.001
SF36-Role Limitations 35.6 (35.1, 36.4) 28.2 (26.6, 29.9) <0.001
Total SF36 Score 95.6 (94.4, 96.8) 82.3 (78.9, 85.7) <0.001
QOLS Score 78.7 (77.6, 79.7) 74.6 (71.9, 77.1) 0.002
Values are mean (95% C.I.)









SF 36-Physical Health 0.3733** 0.3286** 0.2460** 0.3386** 0.4001**
SF36-Mental Health 0.5200** 0.5895** 0.5100** 0.5862** 0.6844**
SF36-Role Limitations 0.3654** 0.3427** 0.3513** 0.3547** 0.4428**
Total SF36 Score 0.5166** 0.5248** 0.4727** 0.5321** 0.6372**
QOLS Score 0.4251** 0.6552** 0.6492** 0.7130 ** 0.7545**
Haemoglobin 0.3444** 0.1908** 0.1607** 0.1752** 0.2761**
Lactate 
Dehydrogenase
-0.3355** -0.1202* -0.2017** -0.1512** -0.2550**
* P < 0.05, ** P < 0.01, based on Student's t test
Health and Quality of Life Outcomes 2009, 7:75 http://www.hqlo.com/content/7/1/75compared favourably with other studies. The Cronbach's
alpha for each of its domains were large, except for WHO-
QOL-Social relations, which is similar to other large, mul-
ticentre trials [32], and may be because it consists of only
three items. The ceiling effects for WHOQOL-Social rela-
tions were also high similar to studies in patients with
chronic obstructive airway disease where the ceiling effect
was 5.2% [27]. In fact the WHOQOL-Bref showed lower
effects than the SF-36, as the latter had high ceiling effects
for two of its domains.
The instrument was able to discriminate between groups
experiencing different frequencies of painful crises. Pain is
a major indicator of health-seeking and hospitalization in
these patients [38,39,42-45], and those with frequent
painful crises have shown poorer QOL in past studies
[9,23]. The WHOQOL-Bref has shown significantly lower
scores in those who have more frequent painful crises.
This mirrors original work by Skevington [46], which has
shown the sensitivity of the WHOQOL instruments to
pain states.
The WHOQOL-Bref score had fair convergent validity,
and the fact that it did not have stronger correlations with
the SF-36 and QOLS suggests that while it does share
some overlap with these existing measures, it assesses a
unique aspect of quality of life not assessed by the either
the SF-36 or the QOL. All domains of the WHOQOL-Bref
had greatest correlations with SF-mental health and sec-
ondly with the total SF-36 score. This may be due to the
fact that SF-physical health is a more objective measure
whereas the WHOQOL-physical health is a purely subjec-
tive measure. This was mirrored in the study comparing
the WHOQOL-Bref with SF-36 in patients with stroke
[41], where the SF-physical health showed low correla-
tions with most domains of the WHOQOL.
WHOQOL-physical health has significant correlations
with more objective clinical variables, i.e. haemoglobin
levels and LDH. Lower haemoglobin and higher LDH lev-
els are known to be associated with more severe SCD
experience [44,47-49]. The expected relationships there-
fore, between WHOQOL-physical health and these clini-
cal parameters have been shown in this study. Similarly,
the WHOQOL-psychological health has shown good con-
vergent validity as evidence by its moderate correlation
with SF-mental health.
Not unlike past research, the present study has also
employed a cross-sectional design to study QOL in SCD,
and so is limited in its ability to examine the stability or
responsiveness to change in QOL in these patients. Future
research could examine how their QOL fluctuates with
changes in their health, as well as how the latter affect test-
retest reliability of QOL instruments.
In conclusion, the WHOQOL-Bref has shown fairly good
utility in this specific disease population. It also compares
favourably to other generic instruments to measure QOL
such as the SF-36 and QOLS.
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